Pomalyst 2234 A Sgm P2023
Defines clinical coverage and authorization criteria for pomalidomide (Pomalyst) including FDA-approved indications and select compendial uses, duration of authorization (typically 12 months), and continuation criteria for reauthorization. Applies when all listed approval criteria are met and member has no exclusions to therapy.
No material changes to policy content or coverage criteria.
Coverage Summary & Indications
Pomalyst (pomalidomide) coverage follows FDA-approved indications and selected compendial uses (NCCN). The policy defines regimen-specific prior therapy requirements for multiple myeloma and grants 12-month authorizations for approved uses. Continuation or reauthorization may be granted for 12 months when there is no evidence of unacceptable toxicity and no evidence of disease progression while on the current regimen.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.